A study published on August 10, 2023 in the journal Nature Communications has identified a new pathway that human immune deficiency virus (HIV) uses to enter the nucleus of a healthy cell, where it can then replicate and go on to invade other cells. The researchers also identified three proteins that are needed for the … Read more
Dosed first patient in Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors Nominated additional oncology target as part of the Company’s collaboration with Moderna to develop in-vivo targeted CAR-M therapies Cash, cash equivalents and marketable securities of $117.1 million expected to fund company through 2024 PHILADELPHIA, … Read more
NEW YORK, Aug. 9, 2023 /PRNewswire/ — Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2023. Recent Business Highlights During and since the second … Read more
Novo Nordisk’s obesity drug Wegovy slashed the risk of serious heart problems by 20% in a large clinical trial. That landmark finding could put more pressure on U.S. insurers to cover the blockbuster medication and similar weight loss treatments. But organizations representing insurers emphasized that the data is still preliminary, and concerns remain about the … Read more
Popular weight-loss drug Wegovy could be made available under more health insurance schemes following the results of a late-stage trial, analysts said Wednesday. Novo Nordisk’s closely watched “SELECT” trial exceeded expectations Tuesday, indicating that Wegovy reduced the risk of major cardiovascular events such as heart attacks or strokes by 20%. “Data like this is going … Read more